Dr. Nagasaka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 The City Dr S
Orange, CA 92868Phone+1 714-456-8000Fax+1 714-456-2242
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2011 - 2014
Certifications & Licensure
HI State Medical License 2021 - 2026
CA State Medical License 2021 - 2025
MI State Medical License 2017 - 2024
SC State Medical License 2013 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer Start of enrollment: 2023 Jul 25
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Start of enrollment: 2021 Sep 01
Roles: Contact
- EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer Start of enrollment: 2023 Jun 01
Roles: Contact
Publications & Presentations
PubMed
- Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and me...Riona Aburaki, Yu Fujiwara, Kohei Chida, Nobuyuki Horita, Misako Nagasaka
Cancer Treatment Reviews. 2024-12-01 - Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Da...Sarah Waliany, Misako Nagasaka, Leah Park, Clara Lam, Zoe Jiang
Cancer Medicine. 2024-12-01 - Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2024-11-30
Press Mentions
AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future OncologyMarch 9th, 2023- AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022August 4th, 2022
- Dr. Nagasaka Named to National 40 Under 40 in Cancer Class of 2020November 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
